Stockscreener 앱 받기
0.9098
10.04%
0.083
시간 외 거래:
.74
-0.1698
-18.66%
Citius Oncology Inc 주식(CTOR)의 최신 뉴스
Breakeven On The Horizon For Citius Oncology, Inc. (NASDAQ:CTOR) - simplywall.st
Citius Pharma Reports First LYMPHIR Revenue of $7.1M in Nine Months - Minichart
Citius Oncology Posts First Revenue from LYMPHIR Launch as Institutional Demand Surges 31% - Minichart
Citius Oncology (NASDAQ:CTOR) Posts Quarterly Earnings Results, Misses Expectations By $0.01 EPS - MarketBeat
Citius Oncology (CTOR) director Jonathan Peri files Form 3 showing no common shares - Stock Titan
Citius Oncology Q3 Results: Sales miss estimate by 40%, EPS inline - scanx.trade
Citius Oncology Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Citius Pharmaceuticals Reports Q3 2026 Financial Results and LYMPHIR Progress - Intellectia AI
CTOR: LYMPHIR launch drove $7.1M revenue and 31% sequential vial order growth, with broad payer access - TradingView
Citius Oncology (CTOR) grows LYMPHIR sales but posts $41M nine-month loss - Stock Titan
Citius Pharmaceuticals, Inc. Reports Fiscal Third Quarter 2026 Financial Results and Provides Business Update - PR Newswire
Citius Oncology (CTOR) investor reports 9.99% beneficial ownership stake - Stock Titan
Citius Oncology appoints independent director Peri to board of directors - ROI-NJ
Citius Oncology appoints Jonathan Peri to board of directors By Investing.com - Investing.com Australia
Citius Oncology Expands Board with Appointment of Independent Director Jonathan Peri - Morningstar
Citius Pharmaceuticals expands Citius Oncology board to nine with appointment of Jonathan Peri - Traders Union
Form 8K Citius Oncology Inc For: 12 August By Investing.com - Investing.com Canada
Citius Oncology adds independent director to expanded board - tipranks.com
Citius Oncology Adds Jonathan Peri to Board as LYMPHIR Commercialization Advances - citybiz
Form 8K Citius Oncology Inc For: 12 August - Investing.com India
Citius Oncology appoints Jonathan Peri to board of directors - Investing.com
Citius Oncology (CTOR) Expected to Announce Earnings on Tuesday - MarketBeat
Citius Oncology Inc (CTOR) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Citius Oncology Inc expected to post a loss of 5 cents a shareEarnings Preview - TradingView
Citius Oncology of Cranford says commercial response to cancer treatment is strong - ROI-NJ
LYMPHIR orders rise 78% QoQ as Citius Oncology expands market access for CTCL treatment. - Pluang
Citius Oncology reports strong LYMPHIR U.S. launch momentum - TipRanks
Citius Oncology reports strong LYMPHIR commercial momentum - TipRanks
Citius Oncology Reports Strong Commercial Momentum for its Cancer Treatment - PR Newswire
CTOR|Citius Oncology Inc|Price:0.654|Chg%:+0.062 - TradingKey
Citius Oncology Inc (CTOR) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Citius Oncology Inc (CTOR) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Citius Oncology, Inc. Revenue Breakdown – NASDAQ:CTOR - TradingView
Citius Oncology Inc (CTOR) Balance Sheet - TradingKey
Citius Oncology Inc (CTOR) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Citius Oncology Inc (CTOR) Income Statement - TradingKey
TradingKey - TradingKey
Citius Oncology Inc (CTOR) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
CTOR|Citius Oncology Inc|Price:0.562|Chg%:-0.016 - TradingKey
CTOR|Citius Oncology Inc|Price:0.570|Chg%:+0.008 - TradingKey
Citius Oncology Inc (CTOR) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Citius Oncology Inc (CTOR) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Citius Oncology (NASDAQ:CTOR) Stock Price Up 0.6%Here's What Happened - marketbeat.com
Citius Pharmaceuticals (CTXR) Sidoti Micro-Cap Virtual Conference Summary - Quartr
Citius Oncology expands sales team for LYMPHIR launch - Investing.com
Citius Oncology expands sales team for LYMPHIR launch By Investing.com - Investing.com Canada
Citius Oncology Reports Nationwide Deployment of LYMPHIR's Broadened Commercial Organization and Expanding Market Adoption - Barchart.com
Citius Oncology expands LYMPHIR launch team nationwide - scanx.trade
Citius Oncology (CTOR) Plunges Over 17% as Selling Pressure MountsMarket Neutral Pair - dars.gov.et
Citius Oncology Inc. (CTOR) Q2 2026 Earnings: Significant EPS Miss with No Reported RevenueEBITDA Analysis - po-news-eg.net
Citius Oncology (Nasdaq: CTOR) sets $18M stock deal at $1.09 to back LYMPHIR launch - Stock Titan
Citius Oncology (CTOR) Registration filing Summary - Quartr
CTXR News | CITIUS PHARMACEUTICALS INC (NASDAQ:CTXR) - ChartMill
CTOR Q1 2026 Earnings: Significant EPS Miss Despite Stock RallyProfit Recovery Report - dars.gov.et
CTOR Q1 2026 Earnings: Significant EPS Miss Signals Ongoing Development-Stage ChallengesEarnings Yield Analysis - dars.gov.et
CTOR Q1 2026 Earnings: Significant EPS Miss as Pre-Revenue Company Posts Wider Than Expected LossOne-Time Gain Impact - dars.gov.et
Enterprise value to EBITDA forward of Citius Oncology, Inc. – NASDAQ:CTOR - TradingView
Price to sales forward of Citius Oncology, Inc. – NASDAQ:CTOR - TradingView
Citius Oncology, Inc. Actuals & Estimates (NASDAQ:CTOR) - TradingView
Citius Oncology, Inc. Actuals & Estimates (BOATS:CTOR) - TradingView
Price to earnings forward of Citius Oncology, Inc. – NASDAQ:CTOR - TradingView
Price to book forward of Citius Oncology, Inc. – NASDAQ:CTOR - TradingView
0.79%
5.15%
자본화:
|
볼륨(24시간):